03/15/23 8:30 AMNasdaq : PRLD earningslow floatPrelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate UpdateFour differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting Cash balance of $201.7 million as of December 31, 2022; runway remains unchangedRHEA-AIpositive
03/15/23 8:00 AMNasdaq : PRLD clinical triallow floatPrelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic CancersPrelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, inRHEA-AIneutral
03/01/23 8:30 AMNasdaq : PRLD conferenceslow floatPrelude Therapeutics To Participate in Barclays Global Healthcare ConferencePrelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Barclays Global Healthcare Conference in Miami, March 14 to 16, 2023. On March 16,RHEA-AIneutral
02/09/23 9:05 AMNasdaq : PRLD conferenceslow floatPrelude Therapeutics To Participate in Two Upcoming Healthcare Investor ConferencesPrelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February. On Tuesday, February 14, at 8:40RHEA-AIneutral
11/14/22 8:00 AMNasdaq : PRLD earningslow floatPrelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business UpdateFDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation CDK4/6 inhibitor) Company to reprioritize clinical pipeline and discontinue PRMT5 program for internal development Strong cash, cash equivalents and marketable securities of $224.0RHEA-AIneutral
10/18/22 8:00 AMNasdaq : PRLD low floatPrelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein DegraderPrelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the U.S. Food and DrugRHEA-AIneutral
09/06/22 8:00 AMNasdaq : PRLD conferenceslow floatPrelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare ConferencesPrelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be participating in two healthcare investment conferences next week in New York City. On Monday,RHEA-AIneutral
08/09/22 8:00 AMNasdaq : PRLD earningslow floatPrelude Therapeutics Announces Second Quarter 2022 Financial Results and Business UpdatePrelude Announces Acceptance of IND For a Differentiated and Brain Penetrant CDK4/6 inhibitor PRT3645 by the US Food and Drug Administration (FDA) Clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 are on track for the second half of 2022RHEA-AIneutral
05/10/22 8:00 AMNasdaq : PRLD earningslow floatPrelude Therapeutics Announces First Quarter 2022 Financial Results and Operations UpdatePrelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022 Strong cash and cash equivalents of $266.2 million as of March 31, 2022, expected to fund operations into 2H2024 WILMINGTON, Del., May 10, 2022RHEA-AIpositive
03/16/22 7:30 AMNasdaq : PRLD earningslow floatPrelude Therapeutics Reports Full Year 2021 Financial ResultsSignificant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients Objectives for 2022: Focused on demonstrating proof-of-concept clinical data for lead pipeline compounds andRHEA-AIpositive